长链非编码RNA H19在食管癌发生发展中的功能及机制研究
[Abstract]:Background Esophageal cancer is one of the most common malignant tumors in the world and has become one of the leading causes of death worldwide. There are two major pathological types of epithelial esophageal cancer: esophageal squamous cell carcinoma and esophageal adenocarcinoma. Although the diagnosis and treatment of esophageal cancer have made great progress, the prognosis of esophageal cancer is still poor, and the overall 5-year survival rate is still at a low level. Effective tumor markers and potential targets for esophageal cancer therapy have become the main directions of basic and clinical research. Only less than 2% of human genome sequences are encoded by proteins. Although other sequences do not encode proteins, more than 90% of them can be transcribed into RNA. Coded RNA. Non-coding RNA participates in many biological processes and plays an important role in tumorigenesis and development. Long chain non coding RNA regulates gene expression at various levels (epigenetic level, transcriptional level and post transcriptional regulation level). A large number of evidence shows that a variety of long-chain non coding RNA have abnormal expression in many kinds of tumors, and play a role in promoting cancer or inhibiting cancer in the process of tumor occurrence and development..HOX transcription RNA (HOTAIR) is the key point of tumor research. In recent years, more and more studies have shown that the abnormal expression of long-stranded non-coding RNA is closely related to the occurrence, development, invasion and metastasis of tumors. Therefore, to explore long-stranded non-coding RNA and protein-coding genes related to tumors. Long-stranded noncoding RNA H19, as a noncoding transcript product of imprinted genes, has no ability to encode proteins because of its paternally imprinted maternal allele expression. H19 has been shown to be highly expressed and has proto-oncogenic activity. However, some studies have suggested that H19 can inhibit the malignant proliferation, invasion, metastasis and neovascularization of tumors. Objective The biological function and pathological mechanism of long-chain non-coding rnah19 in esophageal cancer are still unclear. This study was designed to explore the role of H19 in the occurrence, development and molecular mechanism of esophageal cancer. Materials and Methods 1. The tissue specimens of 64 patients with esophageal cancer who underwent tumor resection in our department from 2007 to 2012 were collected and QR was used. T-pcr was used to quantitatively detect the expression of H19 in 64 esophageal cancer tissues and corresponding normal esophageal tissues, and to analyze the correlation between the expression of H19 and the clinicopathological parameters of patients. 2. the expression of H19 in normal esophageal epithelial cell lines het-1a and esophageal cancer cell lines ec109, ec9706, kyse150 and KYSE450 was detected by qrt-pcr. 3. Silencing the expression of H19 in esophageal cancer cell lines Ec109 and EC9706 by siRNA interference technique, and through CCK-8 method, cell cycle test, in situ tumorigenesis test in nude mice, Transwell cell migration and invasion test The effects of H19 silencing on the expression of MMP-9 protein in EMT epithelial marker e-cadherin, interstitial marker vimentin and its MMPs family were analyzed by Western blot. results 1. The expression of H19 may play an important role in the occurrence and development of esophageal cancer. The expression of H19 is significantly related to the depth of tumor invasion and lymph node metastasis, and is not related to age, sex and tumor differentiation. 2. The detection of H19 in four esophageal cancer cell lines and normal epithelial cell lines confirmed that H19 is present. Esophageal cancer cell lines Ec109 and EC9706 were significantly higher than normal esophageal epithelial cell lines. The proliferation of esophageal cancer cells was significantly inhibited. The g0/g1 phase arrest of esophageal cancer cell lines was detected by flow cytometry. In order to further explore the effect of H19 on the growth of esophageal cancer cells in vivo, we used H19 to interfere with EC9706 cell line and negative control group to carry out subcutaneous tumorigenesis test in nude mice. Subcutaneous tumorigenesis was significantly inhibited, and the tumor volume and weight were significantly lower than those in the negative control group. We further studied the migration and invasion of h19-interfering cell lines Ec109 and EC9706 by Transwell chamber. The results showed that h19-interfering cell lines migration and invasion were significantly inhibited. The results of blot showed that after inhibiting the expression of H19, the expression of E-cadherin, the epithelial markers, and the expression of vimentin and MMP-9 were down-regulated in esophageal cancer cells. As an oncogene promoting tumor cell growth and metastasis, long-stranded non-coding RNA H19 may play an important role in the regulation of metastasis of esophageal cancer and may be a potential therapeutic factor for esophageal cancer. Subtarget.
【学位授予单位】:第三军医大学
【学位级别】:博士
【学位授予年份】:2016
【分类号】:R735.1
【相似文献】
相关期刊论文 前10条
1 代廷荣;;早期发现食管癌[J];农家科技;2002年12期
2 王兆礼,李月生,邵明晓,范加社;食管癌术后急性呼吸窘迫综合征8例分析[J];华北煤炭医学院学报;2004年02期
3 高宗人;河南省食管癌外科治疗的进展及评价[J];河南肿瘤学杂志;2004年06期
4 杨观瑞;食管癌的研究进展[J];现代消化及介入诊疗;2004年03期
5 刘肇瑞;魏文强;黄悦勤;乔友林;吴明;董志伟;;“食管癌早诊早治方案”的经济学评价[J];癌症;2006年02期
6 向明;刘辉;刘俊均;冯亮;岳峰涛;;老年人食管癌手术治疗的体会[J];中华老年多器官疾病杂志;2007年04期
7 罗锋;马洪飚;宋小元;余欣;王睿;;高龄食管癌的外科治疗[J];中国医药指南;2008年24期
8 冯新元;;食管癌术后膈疝的诊治体会[J];中国现代医生;2008年09期
9 马迎光;王胜;赵斌;楮瑞军;;中西医结合治疗食管癌术后功能性胃排空障碍[J];中国医药指南;2009年02期
10 罗荣;黄克峰;陈德荣;战忠利;;食管癌中p33ING1 p53蛋白的表达及临床意义[J];中国肿瘤临床;2009年06期
相关会议论文 前10条
1 高宗人;;积极推进以外科手术为基础的食管癌综合治疗的进展[A];中国第九届全国食管癌学术会议论文集[C];2009年
2 王立东;;环境和遗传对食管癌发生影响的初步研究[A];中国第九届全国食管癌学术会议论文集[C];2009年
3 秦明;常秀军;;高龄食管癌的手术治疗[A];中国第九届全国食管癌学术会议论文集[C];2009年
4 毛友生;赫捷;程贵余;;我国食管癌外科治疗现状与未来对策[A];第十三届中国科协年会第18分会场-癌症流行趋势和防控策略研究研讨会论文集(补充)[C];2011年
5 侯建叶;;食管癌手术病人住院期间的健康教育[A];全国外科护理学术会议暨专题讲座论文汇编[C];2000年
6 陈作敏;杨健;;手术治疗69例食管癌体会[A];2001'全国肿瘤外科学术会议论文汇编[C];2001年
7 夏继国;骆红蕾;;食管癌气管内转移的临床特点[A];2004年全国危重病急救医学学术会议论文集[C];2004年
8 高宗人;;河南省食管癌外科治疗的进展及评价[A];第三届中国肿瘤学术大会教育论文集[C];2004年
9 ;食管癌[A];第三届中国肿瘤学术大会论文集[C];2004年
10 王中林;张蕾;刘宁;陆一民;高克柔;张晓膺;;电视胸腔镜下手术治疗食管癌临床探索[A];第八届华东六省一市胸心血管外科学术会议论文汇编[C];2005年
相关重要报纸文章 前10条
1 天津肿瘤医院食管肿瘤科 于振涛;食管癌术后别平躺[N];健康时报;2008年
2 钱勇;食管癌:早期症状无特异性[N];大众卫生报;2005年
3 高春东;认识食管癌[N];中国中医药报;2004年
4 通讯员 韦夏 本报记者 邓宏鹰 钟少鸿;不良饮食习惯刺激食管易生癌[N];中国食品报;2010年
5 许蓼梅;食管癌术后的饮食调理[N];大众卫生报;2004年
6 罗刚;食管癌外科治疗独木难支[N];健康报;2006年
7 刘东 邹争春;不开胸切食管癌[N];健康报;2007年
8 北京大学第一医院放疗科 高献书 亓昕;食管癌 放疗范围可缩小[N];健康报;2014年
9 记者 李天舒 通讯员 李运红 胡颜;食管癌规范治疗达成专家共识[N];健康报;2011年
10 吴尧;食管癌术后多咳嗽[N];健康时报;2007年
相关博士学位论文 前10条
1 陈陆俊;协同刺激分子B7-H1和B7-H3在食管癌中表达的临床意义及作用研究[D];苏州大学;2015年
2 潘华光;胸腔镜联合腹腔镜技术和加速康复外科措施在食管癌切除术中的临床应用研究[D];安徽医科大学;2015年
3 耿国军;SATB2在食管淲状细胞癌细胞与组织中的表达及其意义[D];郑州大学;2016年
4 邹知耕;阿司匹林抑制食管癌发生与增强顺铂疗效的研究[D];北京协和医学院;2016年
5 谭德立;长链非编码RNA H19在食管癌发生发展中的功能及机制研究[D];第三军医大学;2016年
6 袁翎;食管癌预后和单核苷酸多态性的关系[D];郑州大学;2011年
7 李江伟;食管癌癌前血清分子标志物的研究及应用[D];中国协和医科大学;2005年
8 郭洪;基质金属蛋白酶基因3’端非翻译区多态性与食管癌的关联及其机制研究[D];第三军医大学;2010年
9 郭文忠;食管癌血管形成及抗血管治疗的实验研究[D];中国协和医科大学;2000年
10 王建明;食管癌肿瘤相关基因的遗传与表观遗传学研究[D];复旦大学;2007年
相关硕士学位论文 前10条
1 张艳丽;噎膈血瘀型患者血清对食管癌EC9706细胞PI3K/AKT信号通路和细胞周期的影响[D];河北联合大学;2014年
2 艾思远;ERCC1mRNA、TYMSmRNA在食管癌中的表达及预后研究[D];河北医科大学;2015年
3 刘鹏飞;管状胃在食管癌手术中的临床应用分析[D];泰山医学院;2014年
4 尚健静;Cyfra21-1、SCC和CRP联合检测对食管癌早期诊断价值的探讨[D];泰山医学院;2014年
5 刘三豹;食管癌术后胸腔胃功能的研究[D];河北医科大学;2015年
6 杨金;环氧化酶2在食管癌中的表达及环氧化酶2抑制剂对食管癌小鼠移植瘤生长的影响[D];河北医科大学;2015年
7 赵宇峰;Ⅲ期食管癌同步放化疗与序贯放化疗疗效对比[D];山西医科大学;2014年
8 原鹏;pT2-3N0M0期食管癌术后复发模式及不同辅助治疗方式的比较[D];山西医科大学;2016年
9 李国栋;1510例食管癌患者术后生存率及预后影响因素分析[D];山西医科大学;2016年
10 蔺瑞江;管状胃对食管癌术后并发症和生活质量影响的Meta分析[D];兰州大学;2016年
,本文编号:2190284
本文链接:https://www.wllwen.com/yixuelunwen/zlx/2190284.html